Drug Trial Radar · NCT06465810
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,850
Planned (sponsor's estimate)
Start
Jun 25, 2024
Primary completion
Dec 31, 2031
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- ICON plc
- First posted
- Jun 20, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Conditions
- Transthyretin Amyloidosis
- ATTR-CM
- ATTRv-PN
- ATTR
- ATTR-Mixed
- hATTR
Interventions
Treatment of transthyretin (ATTR) amyloidosis in observational study settingDrug
Data will be collected on patients with ATTR amyloidosis in a real-world setting
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demographic characteristics (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Treatment patterns (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Clinical characteristics (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Findings from biopsy (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Findings from Cardiovascular magnetic resonance imaging (CMR) (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Findings from Bone tracer cardiac scintigraphy (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Findings from Echocardiography (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- ECG variables (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Sural nerve and tibial nerve amplitude (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Biomarker results (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Urine test results (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Clinical manifestations (signs and symptoms) of ATTR amyloidosis (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- 36-Item Short Form Health Survey Version 2 (SF-36v2) Physical Component Summary score (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Norfolk Quality of Life-Diabetic Neuropathy total score (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- New York Heart Association (NYHA) classification (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- National Amyloidosis Centre (NAC) ATTR staging or Mayo staging (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Familial amyloid polyneuropathy (FAP) (Coutinho) staging (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Polyneuropathy disability (PND) score (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Left Ventricular Ejection Fraction (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- 6-minute walk test (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Charlson comorbidity index (CCI) and CCI components (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Other comorbidities of interest (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Healthcare resource utilization (overall and in patients initiating a treatment with eplontersen)Time frame: From time of enrollment for up to 7 years
- Mortality (overall and in patients initiating a treatment with eplontersen)Time frame: Throughout study follow-up (up to 7 years)
- Liver Disease and Live TransplantTime frame: From time of Enrollment for up to 7 Years
Locations
89 sites in 6 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
San Francisco, California · Recruiting
Research Site
San Francisco, California · Recruiting
Research Site
New Haven, Connecticut · Recruiting
Research Site
Washington D.C., District of Columbia · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Indianapolis, Indiana · Recruiting
Research Site
Baltimore, Maryland · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Rochester, Minnesota · Recruiting
Research Site
Kansas City, Missouri · Recruiting
Research Site
St Louis, Missouri · Recruiting
Research Site
New Brunswick, New Jersey · Recruiting
Research Site
Manhasset, New York · Recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Recruiting
Research Site
Durham, North Carolina · Recruiting
Research Site
Portland, Oregon · Recruiting
Research Site
Danville, Pennsylvania · Recruiting
Research Site
Philadelphia, Pennsylvania · Recruiting
Research Site
Philadelphia, Pennsylvania · Recruiting
Research Site
Greenville, South Carolina · Recruiting
Research Site
Germantown, Tennessee · Recruiting
Research Site
Nashville, Tennessee · Recruiting
Research Site
Dallas, Texas · Recruiting
Research Site
Houston, Texas · Not yet recruiting
Research Site
Richmond, Virginia · Recruiting
Research Site
Seattle, Washington · Recruiting
Research Site
Milwaukee, Wisconsin · Recruiting
Research Site
Vancouver, British Columbia, Canada · Recruiting
Research Site
Vancouver, British Columbia, Canada · Recruiting
Research Site
Halifax, Nova Scotia, Canada · Recruiting
Research Site
London, Ontario, Canada · Recruiting
Research Site
Toronto, Ontario, Canada · Recruiting
Research Site
Montreal, Quebec, Canada · Not yet recruiting
Research Site
Rimouski, Quebec, Canada · Not yet recruiting
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.